-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, A50l4CE1JiZ2d0JzZm8UU0FVRGWQhw9GC+e8YFmtBAavO4zEIBqii2PKV/1Je3VW 3F1XwBYkYby7lJrLdcRwTA== 0000950162-02-001853.txt : 20021223 0000950162-02-001853.hdr.sgml : 20021223 20021223114326 ACCESSION NUMBER: 0000950162-02-001853 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20021223 ITEM INFORMATION: Other events ITEM INFORMATION: Financial statements and exhibits FILED AS OF DATE: 20021223 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SHIRE PHARMACEUTICALS GROUP PLC CENTRAL INDEX KEY: 0000936402 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-29630 FILM NUMBER: 02866307 BUSINESS ADDRESS: STREET 1: HAMPSHIRE INTL BUSINESS PARK STREET 2: CHINEHAM BASINGSTOKE CITY: HAMPSHIRE ENGLAND RG STATE: X0 BUSINESS PHONE: 1264333455 MAIL ADDRESS: STREET 1: HAMPSHIRE INTL BUSINESS PARK STREET 2: CHINEHAM BASINGSTOKE CITY: HAMPSHIRE ENGLAND RG STATE: X0 8-K 1 shire8k122302.txt FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 23, 2002 Shire Pharmaceuticals Group plc - -------------------------------------------------------------------------------- (Exact name of registrant as specified in its charter) England and Wales - -------------------------------------------------------------------------------- (State or other jurisdiction of incorporation) 0-29630 98-0359573 (Commission File Number) (IRS Employer Identification No.) Hampshire International Business Park, Chineham, Basingstoke, Hampshire RG24 8EP England - -------------------------------------------------------------------------------- (Address of principal executive offices) (Zip code) Registrant's telephone number, including area code 44 1256 894 000 ------------------------------ - -------------------------------------------------------------------------------- (Former name or former address, if changed since last report) -2- Item 5. Other Events Shire Pharmaceuticals Group plc has issued the press release attached as Exhibit 99.1 and incorporated by reference herein. Item 7. Financial Statements and Exhibits (c) Exhibits. The following exhibit is filed herewith: 99.1 Press Release dated December 23, 2002 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: December 23, 2002 SHIRE PHARMACEUTICALS GROUP PLC By: /s/ Angus Charles Russell ----------------------------------- Name: Angus Charles Russell Title: Group Finance Director -3- EXHIBIT INDEX Number Description 99.1 Press Release dated December 23, 2002 EX-99.1 3 shire8k122302ex.txt PRESS RELEASE Shire Pharmaceuticals Group plc Hampshire International Business Park, Chineham, Basingstoke RG24 8EP UK Tel +44 1256 894000 Fax +44 1256 894708 http://www.shire.com Stock Exchange Announcement 23 December 2002 Shire Pharmaceuticals Group plc (the "Company") The Company announces that on 20 December 2002 Mr Rolf Stahel, an executive director of the Company, exercised expiring share options over the following number of ordinary shares of (pound)0.05p each in the Company: Shares Option Price Option Lapse Date 270,480 (pound)1.00p (i) 23 January 2003 329,095 (pound)1.75p (ii) 14 February 2003 Mr Stahel's decision to exercise these options now has been prompted by their imminent expiry dates and the need to exercise before entering the Company's closed period which will begin on 27 December 2002, for the period up to the release of the Company's full year results at the end of February 2003. Mr Stahel sold 40,480 shares following the exercise of the above options on 20 December at a price of (pound)3.887 per share. Mr Stahel notified the Company on 20 December 2002 that he has also sold 269,520 shares on 20 December 2002 which he had previously acquired on 16 August 2002 through the exercise of a share option, which was due to expire on 23 November 2002. These shares were also sold at (pound)3.887 per share. Both the above sale of shares were made only to enable Mr Stahel to partially fund the cost of exercising the share options and the payment of his associated tax liability arising from these exercises. Mr Stahel has retained all other shares resulting from the share option exercises. As a result of these transactions Mr Stahel has an interest, excluding unexercised share options, in 601,779 ordinary shares of (pound)0.05p each in the Company. In addition Mr Stahel has an interest in share options over 644,927 shares in the Company. Notes: (i) Shire Holdings Limited Share Option Scheme (ii) Shire Pharmaceuticals Executive Share Option Scheme T May Company Secretary For further information please contact: Global (outside US and Canada) Clea Rosenfeld - Investor Relations +44 1256 894 160 US & Canada Gordon Ngan - Investor Relations +1 450 978 7938 Notes to editors Shire Pharmaceuticals Group plc Shire Pharmaceuticals Group plc (Shire) is a rapidly growing international specialty pharmaceutical company with a strategic focus on four therapeutic areas - central nervous system disorders (CNS), oncology, gastro-intestinal (GI) and anti-infectives. Shire also has three platform technologies: advanced drug delivery, lead optimisation for small molecules and biologics. Shire's core strategy is based on research and development combined with in licensing and a focus on eight key pharmaceutical markets. For further information on Shire, please visit the Company's website: www.shire.com -----END PRIVACY-ENHANCED MESSAGE-----